A Phase I, Randomized, Double-blind, Placebo-controlled, Multi-centre, Ascending-dose Trial to Evaluate the Safety, Tolerability and Immunogenicity of Vaccine FP-02.2 in HBeAg-negative Hepatitis B Patients as an add-on Treatment to Entecavir or Tenofovir.
Phase of Trial: Phase I
Latest Information Update: 27 Jul 2017
At a glance
- Drugs FP 02.2 (Primary) ; IC 31
- Indications Hepatitis B
- Focus Adverse reactions; First in man
- Sponsors Altimmune; Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 17 May 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Nov 2017.
- 15 May 2017 Planned End Date changed from 31 Mar 2017 to 1 May 2018.